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Purpose: This prospective study evaluates the results of Endovenous laser ablation (EVLA) for the
treatment of varicose veins.
Methods: Data were prospectively collected for all patients undergoing EVLA for varicose veins in our
unit including clinical outcomes (CEAP classiﬁcation) and post-operative duplex.
Results: 624 EVLA procedures were performed from April 2004 to February 2009. There were 527 LSV
EVLA cases, 449 of which were for the above-knee segment only. There were 94 SSV EVLA cases and 3
patients needed LSV EVLA on the same leg at the same time. 84% were done under general anesthetic
including 126 patients who underwent bilateral procedures at the same session. There were no intra-
operative complications, and a 1% incidence of thrombophlebitis, and <1% incidence of neuropraxia.
During a median follow-up of 20 months (Range 2–51) there was no clinical or duplex evidence of
recurrence and no recannalisation of the treated vein.
Conclusions: Our 5-year experience suggests that EVLA is a safe and effective alternative to conventional
surgery for the treatment of varicose veins. Bilateral procedures were well tolerated by patients even
under local anaesthesia.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Purpose
Ligation and stripping of the long saphenous vein (LSV) and
short saphenous vein (SSV) has been the standard treatment of
varicose veins for decades, yet has a recurrence rate of up to 40% at
5 years, and 20% of all varicose vein operations are for recurrence.1
During the past decade, alternative minimally invasive treat-
ment options such as Endovenous Laser Ablation (EVLA), radio-
frequency ablation, and ultrasound-guided foam sclerotherapy,
have developed. EVLA allows delivery of laser energy directly into
the vein lumen, whereas radiofrequency ablation uses high-
frequency electric current, to produce irreversible occlusion with
subsequent ﬁbrosis. The resultant functional obliteration of the
saphenous vein is less invasive than open surgery and can be per-
formed under local anesthetic as a day case, requiring no hospital
stay. This therefore avoids the complications of open surgery with
comparable outcomes.2,3We have offered EVLA for the treatment of
varicose veins for 5 years with the following results.r and Endovascular surgery,
ospital, Whitechapel, London
777684.
elondon.nhs.uk (C. Kyriakides).
ciates Ltd. Published by Elsevier Lt2. Material and methods
Data prospectively collected on patients who had EVLA for
varicose veins were obtained from our dedicated vascular registry
and showed that from April 2004 to February 2009 we performed
624 EVLA procedures.
Informed consent had been obtained for EVLA in accordancewith
The National Institute for Health and Clinical Excellence (NICE)
recommendations.4 Procedures were performed either under local
(LA) or general anaesthesia (GA), depending on patient and surgeon
preference, with strict aseptic technique. The procedure is the same
for primary and redo-surgery with no modiﬁcations and is as
described in previous publications.5,6
With the patients adequately positioned the venous anatomy is
mapped with duplex ultrasound and marked with an indelible pen.
A 600-nm laser ﬁber (Diomed) is then positioned under ultrasound
guidancewith the tip positioned 2 cm distal to the SFJ or SPJ to avoid
propagation of clot into the deep veins. Tumescent local anesthetic
(100–200 ml of 0.2% Lignocaine) with adrenaline is injected around
the vein under ultrasound guidance. With the power set at 14Watts
for the LSV, and10Watts for the SSV, andafterappropriate laser safety
precautions, laser energy is delivered at 100 J/cm to the LSV and 50 J/
cm to the SSV as the laser ﬁber with its sheath is slowly withdrawnd. All rights reserved.
Table 2
Summary of EVLA procedures.
Total no of EVLA procedures 624
EVLA with phlebectomies 519/624 (83%)
Procedures under General Anesthetic 523/624 (84%)
Mean age 45 þ/ 14 (Range 17–84)
No of male patients 248/624 (40%)
No of Female patients 376/624 (60%)
LSV EVLA 527
Above-knee LSV only 449/527 (85%)
Below-knee LSV only 11/527 (2%)
Full length LSV EVLA 67/527 (13%)
SSV EVLA only 94
LSVþ SSV EVLA (Same leg) 3
Bilateral procedures 126
LSV 113/126 (90%)
SSV 13/126 (10%)
Procedures for Recurrent Disease 77
LSV EVLA ONLY 64/77 (83%)
SSV EVLA ONLY 12/77 (16%)
LSV AND SSV EVLA 1/77 (1%)
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Treatment is stopped about 1 cm above the needle entry point, the
laser is switchedoff, laserandcatheterare removedthen thepuncture
site controlled with a compressive dressing to achieve haemostasis.
Multiple phlebectomies are then performed as required through
micro-stab incisions to sitesmarked pre-operatively with the patient
standing. These incisions are then controlledwithpressure dressings.
Class 2 graduated compression stockings are required for 2
weeks (at all times for the ﬁrst week, then daytime only for the
second week). Oral analgesia is prescribed for at least 5 days,
a combination of Paracetamol and Diclofenac sodium is preferred if
there are no contraindications.
3. Results
From April 2004 to February 2009 we performed 624 EVLA
procedures. 83% of these procedures were combined with extensive
multiple phlebectomies, and 20% were bilateral, with use of general
anaesthesia in 84% to allow complete treatment in one operating
session. The mean age of the patients at operation was 45 (range
17–84) and 60% were female. Clinical severity7 ranged from C1–C5
(Table 1). There were 527 LSV EVLA cases, 449 of which were for the
above-knee segment only. There were 94 SSV EVLA cases and 3
patients needed LSV EVLA on the same leg at the same time (Table 2).
In total, bilateral procedureswere performed in 126 patients,13were
bilateral SSV EVLA.
77(13%) cases were for recurrent varicose veins. 67 patients had
previous ligation þ/ stripping þ/ multiple phlebectomies; 6
patients had previous multiple phlebectomies only; 4 patients had
previous sclerotherapy and the median duration since primary
surgery at time of EVLA was 60months (range 2–360).
Therewereno intra-operative complicationsand immediate post-
procedure duplex ultrasound conﬁrmed echogenic thrombus
formation in all target veinswith no deep vein thrombus. All patients
weredischarged fromhospital the sameday.Onepatientpresented to
the emergency room10days followingbilateral EVLA for bilateral LSV
disease with a pulmonary embolism.8 At 6-week review three
patientswere found to have residual varices, present pre-operatively,
which were subsequently treated by phlebectomies. 3 patients also
went on to receive sclerotherapy for spider veins after EVLA. There
were 6 cases (1%) of thrombophlebitis treated with non-steroidal
drugs which resolved by the 3-month review. 4 patients (<1%)
complained of numbness and 2 patients (<1%) complained of
paraesthesia along the treated vein segment. Over a median follow-
upof 20months (range2–51), therewasnoclinical recurrence andno
recannalisation of the treated LSV or SSV on duplex ultrasound.
4. Discussion
Clinical success of EVLA is deﬁned as permanent occlusion of the
treated vein segments, abolition of reﬂux, successful elimination of
relatedvaricoseveinsand improvement in theclinical classiﬁcationof
the limb by a certain time interval after the procedure.2,7 We per-
formed 624 EVLA procedures; including bilateral procedures, LSV,
SSV and recurrent disease,with a 100% success rate of obliterating the
treated vein with no recurrence over a median time of 20 monthsTable 1
Pre-operative clinical classiﬁcation (CEAP).
(Superﬁcial/reticular veins only) C1 2 limbs
(Simple varicose veins only) C2 414 limbs
(Ankle oedema of venous origin) C3 146 limbs
(Skin pigmentation in the gaiter area) C4 56 limbs
(Healed venous ulcer) C5 6 limbs
(Active venous ulcer) C6 0 limbs(range 2–51). Min et al showed successful occlusion on follow-up
Duplexultrasoundin490/499(98%) limbsat1month,390/396(98.5%)
limbs at 6months, 310/318(97.5%) limbs at 1 year and 113/121(93.4%)
limbs at 2years. 40 patients in the same study were followed up to 3
yearswith no new recurrence;most recurrenceswere found to occur
by 3 months, with no new recurrences after 9 months.9 Our practice
includes multiple phlebectomies via stab incisions for all visible
varicosities after EVLA therapy during the same session.5,6 These
varicosities are marked pre-operatively with the patient in the
standing position and with input from the patient. This way the
patient is less likely to present at a follow-up clinic complaining that
offending varices are still present post-operatively.
The EVLA procedure is the same for primary and recurrent
disease, with no modiﬁcations and is as described in previous
publications.5,6 We did not ﬁnd EVLA for recurrent disease to be
more difﬁcult to perform.
Complications at 6-week review were thrombophlebitis (1%),
numbness (<1%) and paraesthesia (<1%). These were all in patients
who had LSV EVLA and only one of these patients (numbness) had
EVLA for recurrent LSV disease. We observed no such complications
in patients who received SSV EVLA. A possible explanation for this is
the difference in energy density used. We use an energy density of
100 J/cm for the LSV and 50 J/cm for the SSV. The ideal energy
density for EVLA is not known but Timperman et al showed no
treatment failures when an energy density of 80 J/cm or more was
used.10 The optimum energy density delivers enough energy to the
vein wall to cause vein occlusion with minimal thermal damage to
structures outside the vein wall with tumescent analgesia/anes-
thesia. Considering that we use the same amount of tumescent
analgesia/anesthesia in both LSV and SSV EVLA, perhaps a lower
energy density for LSV EVLA would reduce the number of compli-
cations. But a complication rate of 1% is still less than observed in
open ligation and vein stripping.11
There was an incidence of a pulmonary embolism (PE) in a 70 yr
old lady patient who had underwent bilateral EVLA for recurrent LSV
disease 10 days earlier.8 BTS guidelines12 list potential risk factors for
PE, and in this patient they included advanced age, previous bilateral
ligation and stripping of the proximal great saphenous vein a year
earlier,malignancy andphlebitic tributary varices. She hadno clinical
signs of a DVT on presentation with the PE and subsequent duplex
ultrasound showed no propagation of thrombus from the treated
LSVs to thedeepveins. Becauseof this, it is unclear if this lady’sPEwas
a direct consequence of the EVLA procedure, but she was treated
successfully and made a full recovery.
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Clinical Excellence (NICE) inMarch 2004. First described byNavarro
et al for the treatment of incompetent long saphenous vein
segments,13 EVLA avoids the complications of open surgery with
better outcomes. The EVLA procedure has been associated with
minimal scarring (as there is no groin incision), less bruising, faster
recovery and return to normal activity as well as lower recurrence
rates. EVLA is often accompanied by injection sclerotherapy or
multiple avulsions for the removal of residual varicosities.
Comparing EVLA to ligation and stripping; clinical success rates
of EVLA in larger series vary from 93 to98%9,14 compared to tradi-
tional ligation and stripping at 77–82%.15,16 There is also a differ-
ence in recovery time; after EVLA patients are encouraged to
resume normal activity immediatelywithmost returning to normal
activity and work with 1–2 days,9 but series have shown patients
after ligation and stripping on average return to normal activity at
3.9days and return to work at 12.4days.175. Conclusions
Our experience shows EVLA is a safe and effective option in the
treatment of varicose veins. EVLA accurately targets incompetent
veins with on-table ultrasound, and complex dissections associated
with neurovascular injury are avoided. This is a particular advan-
tage in recurrent disease, as it avoids the perils of dissecting
through scar tissue, and for short saphenous disease.Conﬂict of interest
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